Trial Profile
Anti-IgE therapy (omalizumab) in IgE-ACPA positive RA.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2014
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TIGER
- 23 Nov 2009 New trial record
- 23 Nov 2009 New trial record